In a recent announcement, Beam Therapeutics Inc. revealed that Eli Lilly and Company (Lilly) will acquire certain rights from Beam’s collaboration and license agreement with Verve Therapeutics, Inc. This agreement includes Beam’s opt-in rights to co-develop and co-commercialize Verve’s base editing programs for cardiovascular disease, targeting PCSK9, ANGPTL3, and an undisclosed liver-mediated, cardiovascular target.
Under the terms of the agreement, Beam will receive an upfront payment of $200 million and a $50 million equity investment from Lilly. Additionally, Beam is eligible for up to $350 million in potential future development-stage payments, contingent on the completion of specific clinical, regulatory, and alliance milestones, resulting in a potential total deal consideration of up to $600 million.
Beam Therapeutics, a biotechnology company specializing in precision genetic medicines through base editing, views this collaboration as an opportunity to expand its portfolio of clinical and research-stage programs. Base editing is a proprietary technology that enables precise, predictable, and efficient single base changes in targeted genomic sequences, offering a potential therapeutic strategy for various diseases.
Lilly’s interest in this partnership is driven by the potential of single-course gene editing treatments for patients at risk of cardiovascular disease. The collaboration seeks to harness the full potential of Beam’s base editing platform and Verve’s cardiovascular disease programs to develop innovative therapeutic options.
This collaboration reflects Beam’s commitment to advancing genetic medicine and its goal of providing lifelong cures for serious diseases. However, investors should exercise caution, as the success of these endeavors depends on various factors, including regulatory approvals, clinical trial outcomes, and the availability of funding. Beam will continue to pursue its mission while closely monitoring potential risks and uncertainties associated with these developments.
https://www.fiercebiotech.com/biotech/beam-offloads-verve-rights-lilly-600m-and-more-deals-are-works
https://www.globenewswire.com/news-release/2023/10/31/2769940/0/en/Beam-Announces-Agreement-for-Lilly-to-Acquire-Beam-s-Opt-In-Rights-to-Verve-Therapeutics-Base-Editing-Programs-for-Cardiovascular-Disease.html
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services